Longeveron Inc.
LGVNHealthcareNASDAQBiotechnology · Last scanned Oct 22, 2026
Scan Results
Daily timeframeLongeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. At a $4.6M market cap, Longeveron Inc. ranks as a micro-cap company within healthcare. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.
Market Cap
$4.6M
Beta
-0.20
P/E (TTM)
—
P/E (Fwd)
-0.93
EPS (TTM)
$-9.63
EPS (Fwd)
$-1.53
ROE
-203.6%
ROA
-91.0%
Cash
$10.1M
Total Debt
$581,000
Free CF
-$11.6M
52W Change
-82.8%
Annual Financials
Cash vs Debt
Where LGVN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, LGVN finished 80.53% below its 150-day moving average ($7.14) and 79.65% below its 200-day moving average ($6.83). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LGVN overbought or oversold?
At the October 20, 2026 close, LGVN's RSI(14) was 11.6, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Longeveron Inc. holds $10.1M in cash against $581K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$11.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -203.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $1.2M (2022) to $1.2M (2025).
The relatively low beta of -0.20 suggests LGVN is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, LGVN has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LGVN.